CA19-9 Tumor Marker

Cancer antigen 19-9 (CA19-9 tumor marker) refers to a tumor marker associated with pancreatic, gallbladder, colon, and stomach cancers and is also known as an associated gastrointestinal antigen.

CA19-9 cancer marker has high sensitivity and specificity for pancreatic cancer. Detection of CA19-9 tumour marker is helpful for differential diagnosis, disease monitoring, and diagnosis of pancreatic cancer metastasis.

SEKBIO is now offering Mouse anti-human CA19-9 mAb and Humanized anti-human CA19-9 mAb. These antibodies are suitable for use in diagnostics, including ELISA, lateral flow, CLIA, etc. And our products are highly consistent with Roche kits and similar antibodies of CanAg.

CA19-9 Tumor Marker Products

Antibody	Application
Mouse anti-human CA19-9 mAb	For immunodiagnostic: ELISA, LFA, CLIA
Humanized anti-human CA19-9 mAb	For immunodiagnostic: ELISA, LFA, CLIA

CA19-9 Tumor Marker Diagnostic Performance

Tumor Marker CA19-9 Antigen

Cancer antigen 19-9 (CA19-9 antigen) refers to a tumor marker associated with pancreatic cancer, gallbladder cancer, colon cancer, and gastric cancer, also known as a gastrointestinal tract-associated antigen. Cancer antigen 19-9 has high sensitivity and specificity for pancreatic cancer, and its positive rate is between 85% and 95%, and it decreases with the improvement of the condition after surgery.

CA19-9 Tumour Marker Test

The determination of CA19-9 tumour marker is helpful for the differential diagnosis and condition monitoring of pancreatic cancer. When CA19-9 tumour marker is less than 1000 U/ml, it has specific surgical significance. After tumor resection, the concentration of CA19-9 tumour marker will decrease. If it rises again, it can indicate recurrence. The diagnosis of pancreatic cancer metastasis also has a high positive rate. Peripheral metastasis is almost always present when the serum CA19-9 level is higher than 10000 U/ml.

Products

SEKBIO Updates

World Stroke Day: Understanding Stroke Prevention and Management Read More >